Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial

Anticancer Research

Volumn 34, Issue 8, 2014, Pages 4415-4420

  Okegawa, Takatsugu ^a   Higaki, Masao ^b   Matsumoto, Tetsuo ^c   Kase, Hiroshi ^d   Murata, Akihiro ^e   Noda, Kenjiro ^f   Noda, Haruhisa ^g   Asaoka, Hiroshi ^h   Oshi, Masaya ⁱ   Tomoishi, Junzo ^j   Uchida, Hiroji ^k   Higashihara, Eiji ^a   Nutahara, Kikuo ^a  

^a KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION DISASTER MEDICAL CENTER   (Japan)

^c TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^d Sassa General Hospital   (Japan)

^e Kawakita General Hospital   (Japan)

^f Nishi Tokyo Central General Hospital   (Japan)

^g Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^h Akiru Municipal Medical Center   (Japan)

ⁱ TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^j Ome Municipal General Hospital   (Japan)

^k Hitotsubashi Hospital   (Japan)

more..

Author keywords

Prostate cancer; Prostate specific antigen; Zoledronic

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BICALUTAMIDE; COLLAGEN TYPE 1; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; RELEASING FACTOR; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMIDAZOLE DERIVATIVE; PEPTIDE;

ADD ON THERAPY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAILURE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PROSTATE BIOPSY; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; BLOOD; BONE TUMOR; CLINICAL TRIAL; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE TUMOR; URINE; VERY ELDERLY;

BONE METASTASIS; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; COLLAGEN TYPE I; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PEPTIDES; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84907520115     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Zheng M (Zoledronic Acid Prostate Cancer Study Group): Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96(11): 879-882, 2004.
2. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Riicklinger E, Greil R, ABCSG-12 Trial Investigators and Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7): 679-691, 2009.
3. Eidtmann H, de Boer R, Bundred N, Llombart-Cussac A, Davidson N, Neven P, von Minckwitz G, Miller J, Schenk N and Coleman R: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 21(11): 2188-2194, 2010.
4. Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T and Ichikawa T: Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19(2): 169-173, 2012.
5. Nozawa M, Inagaki T, Nagao K, Nishioka T, Komura T, Esa A, Kitagawa M, Imanishi M, Uekado Y, Ogawa T, Kajikawa H, Uejima S, Matsuyama H, Hara I and Uemura H: Phase II trial of zoledronicacid combined with androgen-deprivation therapy for treatment-naive prostate cancer with bone metastasis. Int J Clin Oncol. 2013. DOI10.1007/s10147-013-0604-z
6. Uemura H, Yanagisawa M, Ikeda I, Fujinami K, Iwasaki A, Noguchi S, Noguchi K, Kubota Y; Yokohama Bone Metastasis Study Group: Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial. Int J Clin Oncol 18(3): 472-477, 2013.
7. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC and Lipton A: Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 20(3): 850-856, 2002.
8. Lipton A, Costa L, AH SM and Demers LM: Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27(3): 181-185, 2001.
9. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ and Coleman RE: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97(1): 59-69, 2005.
10. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J and Cook R: Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23(22): 4925-4935, 2005.
11. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE and Coleman RE: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113(1): 193-201, 2008.
12. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S and Moinuddin M: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61(1): 195-202, 1988.
13. Yoshimura N, Nakatsuka K, Saitoh S, Nishizawa Y, Uchiyama M and Miura M: Serum cross-linked N-telopeptide of type I collagen (NTX) and serum amino terminal propeptide of type I procollagen (PΓPN) in residents of a rural community in Japan: reference values classified by age and sex. Osteoporosis 10: 71-76, 2002.
14. Coleman R, Cook R, Hirsh V, Major P and Lipton A: Zoledronic acid use in cancer patients: more than just supportive care? Cancer 117(1): 11-23, 2011.
15. Yasuda Y, Fujii Y, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S and Fukui I: Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol 18(5): 877-883, 2012.
16. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I and Nazmy M: A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 15(4): 382-389, 2010.
17. Mitsiades CS, Bogdanos J, Karamanolakis D, Milathianakis C, Dimopoulos T and Koutsilieris M: Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer. Anticancer Res 26(5B): 3693-3700, 2006.
18. Rajpar S, Massard C, Laplanche A, Tournay E, Gross-Goupil M, Loriot Y, Di Palma M, Bossi A, Escudier B, Chauchercau A and Fizazi K: Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer. Ann Oncol 21(9): 1864-1869, 2010.
19. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR and Eyre DR: A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Rcs 7(11): 1251-1258, 1992.
20. Ali SM, Demers LM, Leitzel K, Harvey HA, Clemens D, Mallinak N, Engle L, Chinchilli V, Costa L, Brady C, Seaman J and Lipton A: Baseline scrum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15(3): 455-459, 2004.